受賞区分：国際学会・会議・シンポジウム等の賞  受賞国：大韓民国

受賞区分：国内学会・会議・シンポジウム等の賞 

記述言語：日本語   出版者・発行元：一般社団法人 日本内分泌外科学会  

<p>甲状腺や副甲状腺に対する頸部手術において，術後出血は初期対応を誤ると致命的な合併症となりうる。頸部のコンパートメントは比較的狭いため，閉創後に皮弁や筋肉・剝離臓器表面や血管断端などから出血をきたすと，コンパートメント内の圧力が上昇し最終的に気道閉塞を引き起こす。その頻度は約0.3～2.2％と報告されており，当科での2019年１月～2023年12月までの直近５年間の頸部手術における後出血頻度は約1.8％であり，いずれも後遺症なく数日後に退院となっている。</p><p>当科では頸部手術後のベッドサイドにラミネート加工された出血時対応プロトコールを常に置き，当科で以前実施した開創時の動画をQRコードの読み取りで閲覧できるようにして当科以外の医師でも初期対応できるよう工夫している。術後出血に対する術前説明は，書面を用いてその文言が書かれた箇所に下線を引くなどして理解の共有を図っており，術直後の家族説明では後出血が発生する可能性について言及している。</p>

DOI： 10.11226/ojjaes.41.3_177

Open Access

CiNii Research

記述言語：日本語   出版者・発行元：一般社団法人 日本内分泌外科学会  

<p>当科においては中リスク甲状腺乳頭癌に対する外科治療方針を2000年以降全摘（TT）＋D3→TT＋両側D1→片葉切除（IL）＋患側D1へde-escalationしてきた。このde-escalationに伴う治療成績を検証することにより中リスク乳頭癌に対する最適な治療方針を検討した。de-escalationしたことにより，未郭清領域である対側の気管周囲リンパ節には約５分の１の症例でリンパ節転移の存在が推測された。しかし，経過観察期間（中央値約６年）において臨床的な再発は患側外側リンパ節の１例であり，生命予後に影響する様な再発はきたしていない。甲状腺全摘を行わないことにより術後放射性ヨウ素治療も行っていないが，予後には影響していないようである。よって，経過観察期間がまだ短いが, 中リスク群に対するIL＋患側D1郭清は妥当な方針と考えられた。</p>

DOI： 10.11226/ojjaes.40.3_140

Open Access

CiNii Research

記述言語：英語   出版者・発行元：Breast Cancer  

In this article the title was incorrectly given as ‘Prognostici of ER-staining patterns and heterogeneity of ER positive HER2 negative breast cancer’ but should have been ‘Prognostic Impact of ER‑staining patterns and heterogeneity of ER positive HER2 negative breast cancer’. The original article has been corrected.

DOI： 10.1007/s12282-025-01729-z

Open Access

Web of Science

Scopus

PubMed

記述言語：英語   出版者・発行元：Breast Cancer  

Background: ATPase copper transporting beta (ATP7B) functions as a copper-transporting ATPase that ejects copper from cells. Although high expression of ATP7B has been reported to increase cisplatin resistance, its role in breast cancer (BC) remains unclear. This study aimed to elucidate the function of ATP7B in BC cells and its significance in patients with BC. Methods: The mRNA and protein expression levels of ATP7B were evaluated in BC and non-cancerous mammary cell lines. Polymerase chain reaction (PCR) array analysis was conducted to determine the correlation between ATP7B and 84 cancer-related genes. ATP7B knockdown was performed using small interfering RNA, and cell proliferation, invasiveness, and migration were analyzed. The associations between the mRNA and protein expression of ATP7B and clinicopathological factors were also investigated in 156 patients with BC. Results: ATP7B was found to be highly expressed in estrogen receptor-positive and human epidermal growth factor receptor 2-positive BC cell lines. PCR array analysis revealed a significant correlation between the expression level of ATP7B and those of cadherin 1, estrogen receptor 1, and MET proto-oncogene. ATP7B knockdown significantly increased the proliferation, invasiveness, and migration of MDA-MB-361 and MDA-MB-415 cells. Patients with high ATP7B expression at the mRNA and protein levels experienced favorable prognoses. In addition, ATP7B expression level was identified as an independent prognostic factor in multivariate analysis. Conclusions: ATP7B is involved in promoting anti-cancer activities of tumor suppressors in BC cells across different subtypes and is considered a prognostic marker for BC.

DOI： 10.1007/s12282-025-01705-7

Open Access

Web of Science

Scopus

PubMed

記述言語：英語   出版者・発行元：Breast Cancer Basic and Clinical Research  

Background: Although BRCA1 and BRCA2 mutations are known to be associated with different breast cancer (BC) subtypes, real-world evidence on how these genetic differences influence tumor behavior and treatment decisions remains limited, particularly in Japanese patients. With the recent expansion of PARP inhibitor indications in Japan, BRCA testing has become increasingly routine, highlighting the need for clinical data tailored to local populations. Objectives: To compare clinicopathological features, recurrence patterns, and surgical choices between BRCA1- and BRCA2-associated BC in Japanese patients, with a focus on ER-positive tumors. Design: A single-institution retrospective cohort study. Methods: We retrospectively reviewed 417 patients who underwent BRCA1/2 genetic testing at a single Japanese institution between April 2020 and November 2023. Of these, 38 patients (12 BRCA1, 26 BRCA2) had pathogenic variants. We compared clinicopathological features, recurrence patterns, and choices of risk-reducing surgery between BRCA1 and BRCA2 carriers. Results: BRCA1-associated cancers were predominantly triple-negative (75%) and diagnosed at earlier stages (T1 in 83.3%), while BRCA2-associated cancers were mainly ER-positive (69.2%) and more likely to present with multiple lymph node metastases (⩾2 nodes in 42.3%). Although Ki-67 levels were higher in BRCA1 tumors, this was largely subtype-dependent. Notably, ER-positive BRCA tumors showed a trend toward higher recurrence. Preferences for prophylactic surgery also varied by mutation type. Conclusion: This single-institution study highlights clinically meaningful differences between BRCA1- and BRCA2-associated BC in Japanese patients. BRCA2 cancers tended to present with more advanced features, while BRCA1 cancers were more often detected at earlier stage. These findings underscore the value of BRCA testing not only for PARP inhibitor eligibility but also for subtype-specific risk assessment and individualized preventive strategies.

DOI： 10.1177/11782234251399355

Open Access

Web of Science

Scopus

PubMed